MAM
INDV icon

Martingale Asset Management’s Indivior Pharmaceuticals INDV Stock Holding History

Martingale Asset Management’s Portfolio INDV Stock Details INDV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.51M Sell
85,564
-53,546
-38% -$1.94M 0.08% 255
2026
Q1 		$4.24M Buy
139,110
+12,050
+9% +$398K 0.11% 194
2025
Q4 		$4.56M Buy
127,060
+31,179
+33% +$952K 0.12% 170
2025
Q3 		$2.31M Buy
95,881
+76,779
+402% +$1.61M 0.06% 280
2025
Q2 		$282K Buy
+19,102
New +$222K 0.01% 715

Other funds holding INDV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
OCM
Oaktree Capital Management Los Angeles, California $7.21B AUM 45.97% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Martingale Asset Management's INDV Position: Q2 2026 in Review

Martingale Asset Management reduced its Indivior Pharmaceuticals (INDV) stake by 38% in Q2 2026, selling an estimated $1.94M and leaving 85,564 shares worth $3.51M. The position accounts for 0.08% of the portfolio, ranked #255.

Martingale Asset Management first reported a position in INDV in Q2 2025 and has held it in 5 quarters since. The position peaked at $4.56M in Q4 2025. 338 funds tracked by Wall St. Rank hold INDV as of Q2 2026.

  • Martingale Asset Management held 85,564 shares of Indivior Pharmaceuticals worth $3.51M as of Q2 2026.
  • Martingale Asset Management sold 53,546 Indivior Pharmaceuticals shares in Q2 2026, an estimated $1.94M.
  • Indivior Pharmaceuticals made up 0.08% of Martingale Asset Management's portfolio in Q2 2026, its #255 holding.
  • Martingale Asset Management first reported a position in Indivior Pharmaceuticals in Q2 2025 and has held it in 5 quarters since.
  • Martingale Asset Management's Indivior Pharmaceuticals position peaked at $4.56M in Q4 2025.
  • 338 funds tracked by Wall St. Rank held Indivior Pharmaceuticals as of Q2 2026.

Based on Martingale Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.